Maze Therapeutics (MAZE) vs Ultragenyx Pharmaceutical (RARE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Maze Therapeutics (MAZE) has outperformed Ultragenyx Pharmaceutical (RARE) over the past year, losing 9.5% versus a loss of 50.5%. Ultragenyx Pharmaceutical is the larger company by market cap ($1.53 billion vs $1.51 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MAZE | RARE |
|---|---|---|
| Share price | $27.11 | $15.48 |
| Market cap | $1.51B | $1.53B |
| 1-day change | +4.75% | +1.24% |
| YTD return | -37.53% | -33.52% |
| 1-year return | -9.49% | -50.45% |
| 5-year return | — | -80.89% |
| Forward P/E | — | 22.87 |
| EPS (TTM) | $-2.48 | $-5.82 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $673.00M |
| Revenue growth (YoY) | — | +20.18% |
| Net income (latest FY) | $-131.12M | $-575.00M |
| Operating margin | — | -79.49% |
| Net margin | — | -85.44% |
| 52-week high | $53.65 | $39.89 |
| 52-week low | $21.95 | $12.73 |
| Distance from 52-week high | -49.47% | -61.19% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +126.85% | +81.20% |
| Average volume | 565.24K | 3.87M |
| Shares outstanding | 55.55M | 98.59M |
| Employees | 141 | 1,371 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- MAZE has outperformed RARE by 41.0 percentage points over the past year.
About Maze Therapeutics
MAZE stock →Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of kidney and metabolic diseases in the United States. Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1, or APOL1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor that is in phase II ready clinical trial for the treatment of phenylketonuria and chronic kidney disease.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 141 employees
About Ultragenyx Pharmaceutical
RARE stock →Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for the treatment of long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.
Health Care · Biotechnology: Pharmaceutical Preparations · 1,371 employees
MAZE vs RARE FAQ
Which is bigger, Maze Therapeutics or Ultragenyx Pharmaceutical?
Ultragenyx Pharmaceutical (RARE) is larger, with a market capitalization of $1.53B compared with $1.51B for Maze Therapeutics (MAZE).
Which stock has performed better over the past year, MAZE or RARE?
MAZE returned -9.49% over the past 12 months, compared with -50.45% for RARE (price return, excluding dividends). Past performance does not predict future results.
Are Maze Therapeutics and Ultragenyx Pharmaceutical in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for Maze Therapeutics and Biotechnology: Pharmaceutical Preparations for Ultragenyx Pharmaceutical.